Clinical trial
Evaluation of the Relationship Between SLMAP and EPO Genetic Polymorphism and the Risk of Diabetic Retinopathy in Egyptian Diabetic Patients: A Case-Control Study
Name
RHDIRB2020110301 REC 72
Description
A case-control study to assess the association between the risk of diabetic retinopathy in Egyptians and genetic polymorphism of both EPO and SLMAP genes.
Trial arms
Trial start
2022-05-20
Estimated PCD
2023-04-30
Trial end
2023-06-30
Status
Completed
Treatment
SLMAP and EPO genetic polymorphism
Presence of EPO gene SNP rs551238 and SLMAP rs17058639 gene polymorphisms
Arms:
cases, controls
Size
180
Primary endpoint
Association of SLMAP gene polymorphism and the risk of confirmed diabetic retinopathy diagnosis
At baseline (upon confirmed diagnosis of diabetic retinopathy)
Association of EPO gene polymorphism and the risk of confirmed diabetic retinopathy diagnosis
At baseline (upon confirmed diagnosis of diabetic retinopathy)
Eligibility criteria
Inclusion Criteria:
* Age \>30-60
* Type 2 DM
* Duration of diabetes from 5-10 years
* Egyptian patients
Exclusion Criteria:
* Other ophthalmic diseases not related to diabetes
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 180, 'type': 'ACTUAL'}}
Updated at
2024-02-07
1 organization
1 product
1 indication
Organization
Ain Shams UniversityIndication
Diabetic Retinopathy